menuMenu
  • WORLDWIDE
  • KONTAKTIRAJTE NAS
  • O NAMA
    close
    • Naše vrijednosti
    • Rukovodstvo
    • Naš način rada
    • Spajanje Tvrtki MSD/Schering-plough
    • Povijest Naše Tvrtke
  • ODGOVORNOST
    close
    • Etika i transparentnost
    • Okoliš
    • Zajednica
    • Prijenos vrijednosti
  • ISTRAŽIVANJE
    close
    • Otkrića i Razvoj
    • Klinički Razvoj
  • PROIZVODI
    close
    • Cjepiva
    • Lijekovi koji se izdaju na recept
  • KARIJERE
    close
    • Život U MSD-u
    • MSD Karijere svijetu
  • O NAMA navigate_next
    • Naše vrijednosti
    • Rukovodstvo
    • Naš način rada
    • Spajanje Tvrtki MSD/Schering-plough
    • Povijest Naše Tvrtke
  • ODGOVORNOST navigate_next
    • Etika i transparentnost
    • Okoliš
    • Zajednica
    • Prijenos vrijednosti
  • ISTRAŽIVANJE navigate_next
    • Otkrića i Razvoj
    • Klinički Razvoj
  • PROIZVODI navigate_next
    • Cjepiva
    • Lijekovi koji se izdaju na recept
  • KARIJERE navigate_next
    • Život U MSD-u
    • MSD Karijere svijetu

Pod pokroviteljstvom Ministarstva zdravlja, u suradnji Hrvatske liječničke komore i tvrtke MSD d.o.o. Hrvatska, više od 9 tisuća liječnika praktičara dobilo je na dar najnovije 18. izdanje MSD medicinskog priručnika koji je preveden na hrvatski jezik.

Cijeli Tekst

 
 

Merck Sharp & Dohme (MSD) je vodeća svjetska farmaceutska tvrtka usmjerena na poboljšanje zdravlja u svijetu

Cijeli Tekst

 
 

MSD je razvio novu terapiju protiv virusa C hepatitisa koji je potencijalno ozbiljna infekcija jetara od koje boluje približno 4 milijuna osoba u Europi.

Cijeli Tekst

 
 

KORISNI LINKOVI
 
 
  • OTHER MSD SITES
    VIJESTI
  • LICENCIRANJE
  • RAZNOLIKOST DOBAVLJAČA
 
 
 

Copyright © Merck Sharp & Dohme d.o.o, Ivana Lučića 2a, 10000 Zagreb, Croatia

  • Forward-Looking Statement
  • Privacy
  • Terms of Use
Image: Circle Close Icon

Forward-Looking Statement ×
 

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.